ATE305473T1 - Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen - Google Patents

Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Info

Publication number: ATE305473T1
Authority: AT; Austria
Prior art keywords: compounds; purification; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1999-11-09

Application number

AT00973192T

Other languages

English (en)

Inventor

Alexander Levitzki

Aviv Gazit

Shmuel Banai

David S Gertz

Gershon Golomb

Frank D Boehmer

Johannes Waltenberger

Original Assignee

Yissum Res Dev Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-09

Filing date

2000-11-02

Publication date

2005-10-15

2000-11-02 Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305473T1 publication Critical patent/ATE305473T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
108091008606 PDGF receptors Proteins 0.000 title 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
238000000746 purification Methods 0.000 title 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 4
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00973192T 1999-11-09 2000-11-02 Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen ATE305473T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/436,651 US6358954B1 (en)	1999-11-09	1999-11-09	PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
PCT/IL2000/000709 WO2001034607A1 (en)	1999-11-09	2000-11-02	Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same

Publications (1)

Publication Number	Publication Date
ATE305473T1 true ATE305473T1 (de)	2005-10-15

Family

ID=23733269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00973192T ATE305473T1 (de)	1999-11-09	2000-11-02	Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Country Status (9)

Country	Link
US (3)	US6358954B1 (de)
EP (1)	EP1228072B1 (de)
JP (1)	JP2003513978A (de)
AT (1)	ATE305473T1 (de)
AU (1)	AU781871B2 (de)
CA (1)	CA2387624A1 (de)
DE (1)	DE60022895T2 (de)
ES (1)	ES2251407T3 (de)
WO (1)	WO2001034607A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358954B1 (en) *	1999-11-09	2002-03-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) *	2001-08-31	2002-08-13	The Research Foundation Of State University Of New York	Method for reducing hypertrophy and ischemia
US7273869B2 (en)	2002-04-08	2007-09-25	Merck & Co., Inc.	Inhibitors of Akt activity
WO2003090686A2 (en)	2002-04-25	2003-11-06	University Of Connecticut Health Center	Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
WO2008093246A2 (en)	2007-02-02	2008-08-07	Vegenics Limited	Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
US8093236B2 (en) *	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US10842669B2 (en)	2008-11-13	2020-11-24	Gholam A. Peyman	Ophthalmic drug delivery method
US20110125090A1 (en) *	2008-11-13	2011-05-26	Peyman Gholam A	Ophthalmic drug delivery system and method
US10272035B2 (en)	2008-11-13	2019-04-30	Gholam A. Peyman	Ophthalmic drug delivery method
US20120040916A1 (en) *	2008-12-22	2012-02-16	Massachusetts Institute Of Technology	Molecular inhibitors of the wnt/beta-catenin pathway
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US9072741B2 (en) *	2009-10-08	2015-07-07	The General Hospital Corporation	Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors
WO2012047225A2 (en) *	2010-10-08	2012-04-12	The General Hospital Corporation	Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4304846A (en) *	1979-02-09	1981-12-08	Ciba-Geigy Ag	Method for processing silver dye-bleach materials
DE3701277A1 (de) *	1987-01-17	1988-07-28	Boehringer Mannheim Gmbh	Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
WO1995006648A1 (fr) *	1993-09-03	1995-03-09	Kyowa Hakko Kogyo Co., Ltd.	Derive d'imidazoquinazoline
AU5108196A (en) *	1995-03-20	1996-10-08	Dr. Karl Thomae Gmbh	Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
EP0863144A4 (de) *	1996-08-30	2001-04-11	Kyowa Hakko Kogyo Kk	Imidazochinazoline
AU8689298A (en)	1997-08-05	1999-03-01	Sugen, Inc.	Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US5990146A (en) *	1997-08-20	1999-11-23	Warner-Lambert Company	Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US5932580A (en) *	1997-12-01	1999-08-03	Yissum Research And Development Company Of The Hebrew University Of Jerusalem	PDGF receptor kinase inhibitory compounds their preparation and compositions
SE9800835D0 (sv) *	1998-03-13	1998-03-13	Astra Ab	New Compounds
WO1999053924A1 (en) *	1998-04-17	1999-10-28	Kyowa Hakko Kogyo Co., Ltd.	Analgetic agent
US6358954B1 (en) *	1999-11-09	2002-03-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same

1999
- 1999-11-09 US US09/436,651 patent/US6358954B1/en not_active Expired - Fee Related
2000
- 2000-11-02 EP EP00973192A patent/EP1228072B1/de not_active Expired - Lifetime
- 2000-11-02 AT AT00973192T patent/ATE305473T1/de not_active IP Right Cessation
- 2000-11-02 ES ES00973192T patent/ES2251407T3/es not_active Expired - Lifetime
- 2000-11-02 JP JP2001536554A patent/JP2003513978A/ja not_active Abandoned
- 2000-11-02 AU AU11730/01A patent/AU781871B2/en not_active Ceased
- 2000-11-02 DE DE60022895T patent/DE60022895T2/de not_active Expired - Fee Related
- 2000-11-02 CA CA002387624A patent/CA2387624A1/en not_active Abandoned
- 2000-11-02 WO PCT/IL2000/000709 patent/WO2001034607A1/en not_active Ceased
2001
- 2001-04-09 US US09/828,602 patent/US6673798B2/en not_active Expired - Fee Related
2003
- 2003-11-19 US US10/715,547 patent/US20040132725A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6358954B1 (en)	2002-03-19
ES2251407T3 (es)	2006-05-01
EP1228072B1 (de)	2005-09-28
EP1228072A1 (de)	2002-08-07
DE60022895D1 (de)	2006-02-09
WO2001034607A1 (en)	2001-05-17
DE60022895T2 (de)	2006-08-24
US20020028817A1 (en)	2002-03-07
US6673798B2 (en)	2004-01-06
AU1173001A (en)	2001-06-06
EP1228072A4 (de)	2003-05-07
CA2387624A1 (en)	2001-05-17
US20040132725A1 (en)	2004-07-08
AU781871B2 (en)	2005-06-16
JP2003513978A (ja)	2003-04-15

Legal Events

Date	Code	Title	Description
2006-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE305473T1 (de)	2005-10-15	Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE232862T1 (de)	2003-03-15	Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
TR199801530T2 (xx)	1998-11-23	VEGF �nhibit�rleri olarak kinazolin t�revleri.
GEP20033131B (en)	2003-12-25	Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
HUP0004040A1 (hu)	2001-05-28	Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE154354T1 (de)	1997-06-15	Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
DE50108674D1 (de)	2006-04-06	Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen
GEP20043161B (en)	2004-01-26	Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
BR0115446A (pt)	2005-08-09	Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
TR200003478T2 (tr)	2001-03-21	Antikanser maddeleri olarak faydalı izotiyazol türevleri
PT928788E (pt)	2003-04-30	Compostos farmaceuticamente activos
DK0583421T3 (da)	1999-11-22	Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
NO996108L (no)	2000-02-10	9-oksinerytromycinderivater
DE68917485D1 (de)	1994-09-22	Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen.
WO2003063787A3 (en)	2004-01-22	Non-steroidal analogs of 2-methoxyestradiol
ATE233754T1 (de)	2003-03-15	Diphenyl-piperidin derivate
TR199801229T2 (xx)	1998-09-21	''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
KR960703863A (ko)	1996-08-31	암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
FR2707638B1 (fr)	1995-08-18	Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
ATE363909T1 (de)	2007-06-15	Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
ATE250610T1 (de)	2003-10-15	Kaliumkanal-blockierende mittel
ES2172179T3 (es)	2002-09-16	Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.
YU46302A (sh)	2005-06-10	Supstituisani piroli
AP9801235A0 (en)	1999-11-07	Erythromycin derivatives.
YU25202A (sh)	2004-12-31	Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera